CL2013000101A1 - Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende. - Google Patents

Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.

Info

Publication number
CL2013000101A1
CL2013000101A1 CL2013000101A CL2013000101A CL2013000101A1 CL 2013000101 A1 CL2013000101 A1 CL 2013000101A1 CL 2013000101 A CL2013000101 A CL 2013000101A CL 2013000101 A CL2013000101 A CL 2013000101A CL 2013000101 A1 CL2013000101 A1 CL 2013000101A1
Authority
CL
Chile
Prior art keywords
understands
antibody
cells
pharmaceutical composition
malignant tumor
Prior art date
Application number
CL2013000101A
Other languages
English (en)
Spanish (es)
Inventor
Stephan Stilgenbauer
Thorsten Zenz
Karl-Heinz Heider
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013000101A1 publication Critical patent/CL2013000101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2013000101A 2010-07-16 2013-01-10 Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende. CL2013000101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07

Publications (1)

Publication Number Publication Date
CL2013000101A1 true CL2013000101A1 (es) 2013-12-27

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000101A CL2013000101A1 (es) 2010-07-16 2013-01-10 Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.

Country Status (15)

Country Link
US (3) US20120189618A1 (enExample)
EP (2) EP2593479A1 (enExample)
JP (2) JP2013538790A (enExample)
KR (1) KR20130100918A (enExample)
CN (2) CN105749276A (enExample)
AU (1) AU2011278227B2 (enExample)
BR (1) BR112013001012A2 (enExample)
CA (1) CA2799036A1 (enExample)
CL (1) CL2013000101A1 (enExample)
EA (1) EA025365B1 (enExample)
IL (1) IL222775A (enExample)
MX (1) MX341463B (enExample)
NZ (2) NZ703225A (enExample)
PH (1) PH12013500118A1 (enExample)
WO (1) WO2012007576A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
EP2849784A1 (en) 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
SG11201707089WA (en) * 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
AU2018236450A1 (en) 2017-03-16 2019-10-03 The General Hospital Corporation Chimeric antigen receptors targeting CD37
UA127586C2 (uk) 2017-03-31 2023-10-25 Ґенмаб Холдінґ Б.В. Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
SG10201403526YA (en) * 2005-07-25 2014-10-30 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2368700T3 (es) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения

Also Published As

Publication number Publication date
CA2799036A1 (en) 2012-01-19
IL222775A0 (en) 2012-12-31
WO2012007576A1 (en) 2012-01-19
KR20130100918A (ko) 2013-09-12
NZ603161A (en) 2015-02-27
MX341463B (es) 2016-08-22
US20120189618A1 (en) 2012-07-26
EP2593479A1 (en) 2013-05-22
MX2012013613A (es) 2012-12-17
JP2017019800A (ja) 2017-01-26
US20130236454A1 (en) 2013-09-12
CN103003309A (zh) 2013-03-27
PH12013500118A1 (en) 2013-03-11
EA025365B1 (ru) 2016-12-30
EP3252077A1 (en) 2017-12-06
AU2011278227A1 (en) 2012-11-15
CN105749276A (zh) 2016-07-13
EA201201660A1 (ru) 2013-07-30
JP2013538790A (ja) 2013-10-17
US20150266967A1 (en) 2015-09-24
BR112013001012A2 (pt) 2016-05-24
NZ703225A (en) 2016-11-25
IL222775A (en) 2017-10-31
AU2011278227B2 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
CL2013000101A1 (es) Anticuerpo cd37 para tratar tumor maligno de celulas b; composicion farmacéutica que lo comprende.
IL289300A (en) Combination therapy for treating cancer
IL282953A (en) Agents for treatment of claudin expressing cancer diseases
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
IL262073B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
BR112014027477A2 (pt) métodos de processamento de materiais lingnocelulósicos.
WO2013123152A3 (en) ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
IL230662A0 (en) Indazoles
EP3702368C0 (en) ANTIGEN-BINDING MOLECULES PROMOTING ANTIGEN CLEARANCE
EP3421496C0 (en) ANTIBODIES FOR THE TREATMENT OF CANCER EXPRESSING CLAUDIN 6
PT2632452T (pt) Compostos e composições para o tratamento do cancro
IL224370B (en) Combination treatment for prostate carcinoma
HUE048876T2 (hu) Rákos megbetegedések kezelése
PL2739153T3 (pl) Leczenie raka sutka
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
CL2014001640A1 (es) Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo.
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
EP2847254A4 (en) CHEMICAL MODIFICATION OF LIGNIN AND LIGNIN DERIVATIVES
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
FR2955770B1 (fr) Composition cosmetique.
EP2847255A4 (en) CHEMICAL MODIFICATION OF LIGNIN AND LIGNIN DERIVATIVES